Yazar "Nasri, Negar" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    A comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapy
    (Elsevier, 2023) Saharkhiz, Shaghayegh; Zarepour, Atefeh; Nasri, Negar; Cordani, Marco; Zarrabi, Ali
    Chemotherapy agents often exhibit limited effectiveness due to their fast elimination from the body and nontargeted delivery. Emerging nanomaterials as drug delivery carriers open new expectancy to overcome these limitations in current chemotherapeutic treatments. In this study, we introduce and evaluate a smart pHresponsive niosomal formulation capable of delivering Doxorubicin (DOX) and Curcumin (CUR) in both individually and co-loaded forms. In particular, drug-loaded niosomes were prepared using thin-film hydration method and then characterized via different physicochemical analyses. The pH responsivity of the carrier was assessed by performing a drug release study in three different pH conditions (4, 6.5, and 7.4). Finally, the anticancer efficacy of the therapeutic compounds was evaluated through the MTT assay. Our results showed spherical particles with a size of about 200 nm and -2 mV surface charge. Encapsulation efficiency (EE%) of the nanocarrier was about 77.06 % and 79.08 % for DOX and CUR, respectively. The release study confirmed the pH responsivity of the carrier. The MTT assay results revealed about 39 % and 43 % of cell deaths after treatment with cur-loaded and dox-loaded niosomes, which increased to 74 % and 79 % after co-administration and coloading forms of drugs, respectively, exhibiting increased anticancer efficacy by selectively delivering DOX and CUR individually or in combination. Overall, these findings suggest that our nanoformulation holds the potential as a targeted and highly effective approach for cancer management and therapy, overcoming the limitations of conventional chemotherapy drugs.
  • Küçük Resim Yok
    Öğe
    Development of pH and thermo-responsive smart niosomal carriers for delivery of gemcitabine to the breast cancer cells
    (Springernature, 2024) Ghalehshahi, Saeid Shirzadi; Saharkhiz, Shaghayegh; Naderi, Nazanin; Nasri, Negar; Saharkhiz, Shiva; Zarepour, Atefeh; Goodarzi, Reza
    The utilization of intelligent drug carriers in cancer therapy has emerged as a transformative paradigm in modern oncology. These advanced drug delivery systems exploit the distinctive characteristics of cancer cells and their surrounding microenvironment to attain precise and targeted drug release at the tumor site. In this study, we aim to introduce a novel niosome formulation endowed with dual-responsive properties, pH, and thermo-sensitivity, to enhance drug release precisely within the intended target site. Therefore, thin-film method was used for the fabrication of niosomes, incorporating dipalmitoylphosphatidylcholine (DPPC), as thermoresponsive phospholipid, and citraconic anhydride, as pH-responsive linker. The fabricated niosomes were evaluated through physicochemical analysis using Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and scanning electron microscopy (SEM). Additionally, the entrapment efficiency (EE%) and drug release pattern of gemcitabine (GEM) were quantified at different conditions using UV-Visible spectroscopy. The bioactivity of these niosomes was also evaluated via cytotoxicity assay and flow cytometry. Results of physicochemical analysis verified the successful fabrication of spherical nanoparticles, with a size range of about 100-150 nm and a neutral surface charge. Furthermore, the fabricated niosomes showed sensitivity to acidic pH (6.5) and temperature exceeding the transition temperature (Tc) of the DPPC (41.5 degrees C). Importantly, the drug release profile indicated about 10-17% enhancement in drug release for the dual-stimuli platform in comparison to the single-stimuli ones. The cytotoxicity assay and flow cytometry analysis demonstrated an approximate 10% increase in cytotoxicity and about a 2.5-fold rise in apoptosis induction for the dual-stimuli responsive platform in contrast to the free drug. In conclusion, this dual-stimuli responsive nanocarrier presents a promising strategy to enhance the specificity and efficacy of cancer chemotherapy while simultaneously reducing the adverse side effects experienced by patients.